Telehealth Cerebral Cuts Staff Amid Industry Slowdown and Federal Investigations

Sign up for smart news, insights, and analysis on the biggest financial stories of the day.
The age of the digital Dr. Feelgood may be drawing to a close.
Cerebral, a telehealth company that’s allegedly too quick to prescribe new patients medications, is cutting 20% of its staff as it shrinks operations, according to a Monday report from The Wall Street Journal.
The Doctor Will Zoom You Now
Under nerve-wracking lockdowns, many seeking mental treatment turned to digital health startups like Cerebral, Done, and Sympatient. But the success had a short half-life, plus nasty side effects.
Operating on 30-minute phone calls, doctors and nurse practitioners said they felt pressured to prescribe Adderall – a controlled substance to treat ADHD that was plastered all over Cerebral and Done’s social media ads. Adderall prescriptions in the US jumped to 41.4 million in 2021, up 10.4% from 2020, according to Iqvia Holdings Inc., a data and research services provider. In 2021, the digital health industry as a whole raised $29.2 billion in venture capital, according to Rock Health, a San Francisco-based venture investor and advisory firm. Now under investigation by the FTC and the DOJ for haphazardly writing prescriptions, Cerebral is also cutting costs and employees as they navigate a digital health industry on the come down:
- A Cerebral spokesperson told the WSJ the shrinking was to match patient demand and lower growth targets. By Q3, digital-health startups have collected only $12.6 billion, not even half of last year’s venture capital investments. Earlier this month, the company also announced it would phase out providing new patients with care counseling.
- In a memo to his staff, CEO Dr. David Mou said, “These are challenging times for many companies. In order to continue to work towards our mission, we have a duty to our patients to ensure our business is healthy and sustainable throughout challenging economic times.”
In Poor Health: Startups are ailing but so are 100-year-old conglomerates. Just days after taking the helm of Philips, a medical equipment business, CEO Roy Jakobs announced the company would cut 4,000 jobs, roughly 5% of its workforce. In one year, shares at Philips plunged 73% from $48 to $13. Luckily, the company does sell defibrillators.